Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

M Saleh^*, M Barve, V Subbiah, K P Papadopoulos, D Morgensztern, N B Mettu, S Roychowdhury, I Spanggaard, M L Veronese, C Tian, I M Silverman, M Gutierrez

^*Corresponding author for this work